Rocket Pharmaceuticals, Inc.
RCKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.09 | 0.31 | 0.40 |
| FCF Yield | -13.85% | -18.02% | -7.65% | -3.85% |
| EV / EBITDA | -5.99 | -4.01 | -12.27 | -18.92 |
| Quality | ||||
| ROIC | -15.38% | -18.70% | -14.68% | -12.80% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.00 | 0.71 | 0.91 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -2.76% | 12.72% | -18.84% | 11.99% |
| Safety | ||||
| Net Debt / EBITDA | 0.97 | 0.12 | 0.42 | 2.40 |
| Interest Coverage | 110.46 | -150.42 | -136.42 | -132.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -60.58 | -88.68 | 0.00 |